Evommune (EVMN) grants CFO 98,946 options at $26.77 strike

Rhea-AI Filing Summary

Evommune, Inc. reported that Chief Financial Officer Kyle Carver received an employee stock option grant. The award covers 98,946 shares of common stock at an exercise price of $26.77 per share and expires on April 15, 2036.

According to the vesting terms, one fourth of the option vests on the first anniversary of the grant, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to his continuous service. Following this grant, he holds 98,946 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Carver Kyle

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	98,946	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 98,946 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 98,946 shares Exercise price: $26.77 per share Expiration date: April 15, 2036 +3 more

6 metrics

Option shares granted 98,946 shares Employee stock option award to CFO on April 16, 2026

Exercise price $26.77 per share Strike price for employee stock option

Expiration date April 15, 2036 Option term for CFO grant

Post-grant derivative holdings 98,946 derivative securities Total options held directly after transaction

Initial vesting tranche 25% of shares Vests on first anniversary of grant date

Subsequent vesting schedule 36 monthly installments Remaining option shares vest monthly after first year

Key Terms

Employee Stock Option (Right to Buy), exercise price, Common Stock, vesting, +1 more

5 terms

Employee Stock Option (Right to Buy) financial

"security_title: "Employee Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "26.7700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"shares subject to the option award shall vest on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carver Kyle

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$26.77	04/16/2026		A		98,946		(1)	04/15/2036	Common Stock	98,946	$0.00	98,946	D

Explanation of Responses:

1. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Evommune (EVMN) disclose about CFO Kyle Carver’s latest equity grant?

Evommune disclosed that CFO Kyle Carver received an employee stock option for 98,946 shares of common stock. The options have an exercise price of $26.77 per share and represent a routine compensation-related equity award rather than an open-market purchase.

What are the key terms of Kyle Carver’s Evommune (EVMN) stock options?

The option gives CFO Kyle Carver the right to buy 98,946 Evommune shares at an exercise price of $26.77 per share. The award expires on April 15, 2036, setting a long-term window during which he may choose to exercise the options.

How do Kyle Carver’s Evommune (EVMN) stock options vest over time?

One fourth of the granted options vest on the first anniversary of the grant date. The remaining shares vest in 36 equal monthly installments afterward, and all vesting is conditioned on Kyle Carver’s continuous service with Evommune through each vesting date.

Is Kyle Carver’s Evommune (EVMN) option grant an open-market stock purchase?

No, the filing describes a compensation-related stock option grant coded as an acquisition (A), not an open-market purchase. The options are exercisable at $26.77 per share and vest over time rather than reflecting immediate buying of common stock in the market.

How many Evommune (EVMN) derivative securities does Kyle Carver hold after this grant?

Following the grant, the filing shows Kyle Carver holding 98,946 derivative securities directly. These represent options linked to Evommune common stock, providing the right to purchase shares in the future at the fixed exercise price of $26.77 per share.